| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mesothelioma | 107 | 2024 | 323 | 17.970 |
Why?
|
| Pleural Neoplasms | 67 | 2024 | 198 | 12.180 |
Why?
|
| Pancreatic Neoplasms | 57 | 2023 | 666 | 9.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 70 | 2024 | 2552 | 5.380 |
Why?
|
| Lung Neoplasms | 64 | 2024 | 2347 | 4.830 |
Why?
|
| Deoxycytidine | 38 | 2020 | 238 | 4.390 |
Why?
|
| Adenocarcinoma | 33 | 2022 | 1194 | 4.210 |
Why?
|
| Neoplasm Staging | 50 | 2024 | 2001 | 3.460 |
Why?
|
| Phthalazines | 7 | 2023 | 45 | 3.040 |
Why?
|
| Antineoplastic Agents | 40 | 2020 | 2411 | 2.550 |
Why?
|
| Peritoneal Neoplasms | 14 | 2024 | 184 | 2.460 |
Why?
|
| Antimetabolites, Antineoplastic | 21 | 2018 | 244 | 2.390 |
Why?
|
| Aged | 160 | 2024 | 19077 | 2.180 |
Why?
|
| Aged, 80 and over | 99 | 2024 | 6777 | 2.030 |
Why?
|
| Middle Aged | 158 | 2024 | 25863 | 1.880 |
Why?
|
| Humans | 266 | 2024 | 89063 | 1.770 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 1363 | 1.670 |
Why?
|
| Piperazines | 7 | 2019 | 283 | 1.640 |
Why?
|
| Colonic Neoplasms | 15 | 2022 | 573 | 1.630 |
Why?
|
| Gastrointestinal Neoplasms | 4 | 2020 | 111 | 1.620 |
Why?
|
| Germ-Line Mutation | 13 | 2023 | 344 | 1.610 |
Why?
|
| Female | 169 | 2024 | 46011 | 1.600 |
Why?
|
| Male | 167 | 2024 | 42251 | 1.600 |
Why?
|
| Antibodies, Monoclonal | 18 | 2024 | 1400 | 1.580 |
Why?
|
| Antibodies, Monoclonal, Humanized | 23 | 2024 | 967 | 1.530 |
Why?
|
| Antineoplastic Agents, Immunological | 7 | 2021 | 195 | 1.440 |
Why?
|
| Stomach Neoplasms | 9 | 2020 | 281 | 1.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2023 | 112 | 1.420 |
Why?
|
| Glutamates | 15 | 2014 | 89 | 1.380 |
Why?
|
| Pemetrexed | 21 | 2021 | 76 | 1.370 |
Why?
|
| Fluorouracil | 17 | 2020 | 561 | 1.350 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 84 | 1.350 |
Why?
|
| Adult | 109 | 2024 | 26507 | 1.310 |
Why?
|
| Survival Rate | 32 | 2024 | 1889 | 1.310 |
Why?
|
| Guanine | 15 | 2014 | 207 | 1.300 |
Why?
|
| Colorectal Neoplasms | 16 | 2024 | 981 | 1.290 |
Why?
|
| Treatment Outcome | 62 | 2023 | 8203 | 1.200 |
Why?
|
| Immunoconjugates | 4 | 2024 | 110 | 1.200 |
Why?
|
| BRCA1 Protein | 5 | 2020 | 204 | 1.200 |
Why?
|
| Pyridines | 7 | 2016 | 315 | 1.190 |
Why?
|
| Disease-Free Survival | 26 | 2022 | 1214 | 1.180 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2016 | 604 | 1.130 |
Why?
|
| Ovarian Neoplasms | 3 | 2023 | 763 | 1.110 |
Why?
|
| Esophageal Neoplasms | 6 | 2020 | 332 | 1.080 |
Why?
|
| BRCA2 Protein | 4 | 2020 | 161 | 1.070 |
Why?
|
| Cisplatin | 19 | 2021 | 617 | 1.050 |
Why?
|
| Neoplasms | 24 | 2023 | 3035 | 1.010 |
Why?
|
| Prognosis | 30 | 2024 | 3773 | 0.970 |
Why?
|
| Bevacizumab | 16 | 2023 | 287 | 0.940 |
Why?
|
| Quinazolines | 7 | 2012 | 221 | 0.940 |
Why?
|
| Leucovorin | 11 | 2020 | 224 | 0.920 |
Why?
|
| Glucuronosyltransferase | 3 | 2020 | 186 | 0.910 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2020 | 859 | 0.860 |
Why?
|
| Survival Analysis | 24 | 2020 | 1533 | 0.840 |
Why?
|
| Biomarkers, Tumor | 15 | 2024 | 1543 | 0.830 |
Why?
|
| Camptothecin | 9 | 2017 | 193 | 0.820 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2019 | 77 | 0.810 |
Why?
|
| Pyrimidines | 7 | 2016 | 372 | 0.810 |
Why?
|
| Pneumonectomy | 8 | 2023 | 206 | 0.770 |
Why?
|
| Diet | 7 | 2022 | 442 | 0.760 |
Why?
|
| Genes, BRCA2 | 2 | 2019 | 161 | 0.760 |
Why?
|
| Genes, BRCA1 | 2 | 2019 | 192 | 0.750 |
Why?
|
| Liver Neoplasms | 11 | 2011 | 754 | 0.720 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 285 | 0.710 |
Why?
|
| Quality of Life | 11 | 2023 | 1662 | 0.700 |
Why?
|
| Neoplasm Metastasis | 16 | 2024 | 1108 | 0.680 |
Why?
|
| Clinical Trials as Topic | 16 | 2019 | 1149 | 0.650 |
Why?
|
| Angiogenesis Inhibitors | 6 | 2021 | 315 | 0.640 |
Why?
|
| GPI-Linked Proteins | 6 | 2024 | 51 | 0.630 |
Why?
|
| Vascular Endothelial Growth Factor A | 8 | 2021 | 421 | 0.620 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2022 | 485 | 0.620 |
Why?
|
| Double-Blind Method | 13 | 2019 | 1714 | 0.620 |
Why?
|
| Disease Progression | 12 | 2023 | 1488 | 0.610 |
Why?
|
| Drug Administration Schedule | 14 | 2019 | 894 | 0.590 |
Why?
|
| Biliary Tract Neoplasms | 3 | 2019 | 33 | 0.580 |
Why?
|
| Organoplatinum Compounds | 6 | 2017 | 97 | 0.570 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2022 | 2657 | 0.570 |
Why?
|
| Rare Diseases | 1 | 2016 | 65 | 0.540 |
Why?
|
| Combined Modality Therapy | 12 | 2023 | 1710 | 0.540 |
Why?
|
| Hedgehog Proteins | 2 | 2016 | 100 | 0.530 |
Why?
|
| Anilides | 1 | 2015 | 48 | 0.510 |
Why?
|
| Maytansine | 4 | 2024 | 10 | 0.510 |
Why?
|
| Gallbladder Neoplasms | 2 | 2005 | 23 | 0.510 |
Why?
|
| Asbestos | 2 | 2013 | 22 | 0.490 |
Why?
|
| Follow-Up Studies | 22 | 2022 | 3657 | 0.490 |
Why?
|
| Radiation Injuries | 6 | 1999 | 160 | 0.490 |
Why?
|
| Neoadjuvant Therapy | 6 | 2018 | 373 | 0.490 |
Why?
|
| Germ Cells | 3 | 2022 | 130 | 0.470 |
Why?
|
| Bile Duct Neoplasms | 2 | 2005 | 90 | 0.470 |
Why?
|
| Salvage Therapy | 3 | 2010 | 235 | 0.460 |
Why?
|
| Thiazoles | 2 | 2012 | 128 | 0.460 |
Why?
|
| Folic Acid Antagonists | 4 | 2008 | 19 | 0.460 |
Why?
|
| Maximum Tolerated Dose | 14 | 2021 | 272 | 0.450 |
Why?
|
| Prospective Studies | 22 | 2024 | 4273 | 0.450 |
Why?
|
| Pyrazines | 6 | 2019 | 94 | 0.450 |
Why?
|
| Ubiquitin Thiolesterase | 8 | 2023 | 65 | 0.430 |
Why?
|
| Radioactive Hazard Release | 4 | 1999 | 8 | 0.410 |
Why?
|
| Epothilones | 2 | 2009 | 13 | 0.400 |
Why?
|
| Pleura | 4 | 2018 | 31 | 0.390 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 159 | 0.390 |
Why?
|
| Imidazoles | 2 | 2014 | 148 | 0.380 |
Why?
|
| User-Computer Interface | 6 | 1999 | 187 | 0.380 |
Why?
|
| Indazoles | 1 | 2011 | 67 | 0.370 |
Why?
|
| Neutropenia | 9 | 2019 | 216 | 0.370 |
Why?
|
| Medical Oncology | 3 | 2018 | 382 | 0.370 |
Why?
|
| Retrospective Studies | 17 | 2024 | 9003 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2024 | 2399 | 0.360 |
Why?
|
| Proportional Hazards Models | 11 | 2022 | 848 | 0.350 |
Why?
|
| Platelet-Derived Growth Factor | 3 | 2011 | 67 | 0.350 |
Why?
|
| Neuroendocrine Tumors | 3 | 2023 | 117 | 0.350 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 479 | 0.350 |
Why?
|
| Child Abuse | 1 | 2010 | 83 | 0.340 |
Why?
|
| Hyperinsulinism | 2 | 2020 | 47 | 0.340 |
Why?
|
| Preoperative Care | 3 | 2018 | 396 | 0.340 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2023 | 287 | 0.330 |
Why?
|
| Infusions, Intravenous | 10 | 2009 | 434 | 0.330 |
Why?
|
| Mass Screening | 2 | 2011 | 636 | 0.330 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2009 | 16 | 0.330 |
Why?
|
| Paclitaxel | 6 | 2021 | 479 | 0.320 |
Why?
|
| Polyethylene Glycols | 2 | 2024 | 358 | 0.320 |
Why?
|
| Carboplatin | 6 | 2021 | 304 | 0.320 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2005 | 277 | 0.320 |
Why?
|
| Oxides | 1 | 2008 | 43 | 0.320 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2008 | 23 | 0.320 |
Why?
|
| Placebos | 4 | 2015 | 214 | 0.320 |
Why?
|
| Arsenicals | 1 | 2008 | 48 | 0.320 |
Why?
|
| Benzamides | 6 | 2019 | 237 | 0.310 |
Why?
|
| Expert Systems | 3 | 1998 | 18 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 1239 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2019 | 1940 | 0.300 |
Why?
|
| Genotype | 4 | 2020 | 1848 | 0.300 |
Why?
|
| Tomography, Emission-Computed | 1 | 2007 | 102 | 0.300 |
Why?
|
| Life Style | 4 | 2022 | 172 | 0.300 |
Why?
|
| Databases, Factual | 4 | 2024 | 850 | 0.300 |
Why?
|
| Genome-Wide Association Study | 5 | 2024 | 1670 | 0.300 |
Why?
|
| Signal Transduction | 5 | 2016 | 3373 | 0.290 |
Why?
|
| Cholangiocarcinoma | 2 | 2005 | 76 | 0.290 |
Why?
|
| Medical Records Systems, Computerized | 2 | 1999 | 40 | 0.290 |
Why?
|
| Hypertension | 3 | 2021 | 741 | 0.280 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2023 | 76 | 0.280 |
Why?
|
| Dietary Sucrose | 2 | 2018 | 13 | 0.280 |
Why?
|
| Sweetening Agents | 2 | 2018 | 17 | 0.280 |
Why?
|
| Thymidylate Synthase | 2 | 2004 | 13 | 0.280 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2016 | 185 | 0.280 |
Why?
|
| Internet | 2 | 1999 | 318 | 0.270 |
Why?
|
| Young Adult | 13 | 2024 | 6288 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 1043 | 0.270 |
Why?
|
| Cancer Survivors | 2 | 2018 | 95 | 0.270 |
Why?
|
| Precision Medicine | 3 | 2017 | 410 | 0.260 |
Why?
|
| Vitamin D | 3 | 2018 | 268 | 0.260 |
Why?
|
| Indoles | 6 | 2011 | 312 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2016 | 200 | 0.250 |
Why?
|
| Sulfonamides | 5 | 2019 | 317 | 0.240 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 63 | 0.240 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2024 | 17 | 0.240 |
Why?
|
| Oligopeptides | 1 | 2005 | 188 | 0.240 |
Why?
|
| Hydrolases | 1 | 2024 | 30 | 0.240 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 166 | 0.230 |
Why?
|
| Risk Factors | 11 | 2024 | 5466 | 0.230 |
Why?
|
| United States | 11 | 2021 | 6955 | 0.230 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2004 | 307 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2010 | 616 | 0.220 |
Why?
|
| Boronic Acids | 3 | 2010 | 56 | 0.220 |
Why?
|
| Benzimidazoles | 3 | 2020 | 111 | 0.220 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2015 | 55 | 0.220 |
Why?
|
| Models, Theoretical | 1 | 2006 | 491 | 0.220 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2017 | 23 | 0.220 |
Why?
|
| Genomics | 3 | 2023 | 761 | 0.220 |
Why?
|
| Albumins | 2 | 2020 | 129 | 0.220 |
Why?
|
| Mutation | 7 | 2020 | 4132 | 0.220 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2013 | 45 | 0.210 |
Why?
|
| RNA, Long Noncoding | 1 | 2024 | 117 | 0.210 |
Why?
|
| Exercise | 2 | 2018 | 322 | 0.210 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 271 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2023 | 2335 | 0.210 |
Why?
|
| Neurofibromin 2 | 2 | 2019 | 30 | 0.210 |
Why?
|
| Artificial Intelligence | 4 | 2005 | 322 | 0.210 |
Why?
|
| Arthrogryposis | 1 | 2022 | 7 | 0.210 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2023 | 64 | 0.210 |
Why?
|
| Pilot Projects | 4 | 2018 | 865 | 0.210 |
Why?
|
| Red Meat | 1 | 2022 | 10 | 0.200 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2013 | 172 | 0.200 |
Why?
|
| Nomograms | 1 | 2022 | 29 | 0.200 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2021 | 16 | 0.200 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2021 | 14 | 0.200 |
Why?
|
| Chicago | 2 | 2020 | 1423 | 0.200 |
Why?
|
| Sarcoma | 1 | 2023 | 220 | 0.200 |
Why?
|
| Photography | 2 | 1998 | 37 | 0.200 |
Why?
|
| Neoplasm Grading | 2 | 2020 | 372 | 0.200 |
Why?
|
| Proteinuria | 1 | 2021 | 67 | 0.190 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2007 | 333 | 0.190 |
Why?
|
| Genetic Testing | 3 | 2023 | 537 | 0.190 |
Why?
|
| Enzyme Inhibitors | 2 | 2005 | 645 | 0.190 |
Why?
|
| Beverages | 2 | 2018 | 17 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2006 | 1114 | 0.190 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2016 | 88 | 0.190 |
Why?
|
| Nausea | 6 | 2020 | 176 | 0.190 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 228 | 0.190 |
Why?
|
| CD40 Antigens | 1 | 2021 | 44 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2019 | 2290 | 0.190 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 26 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 260 | 0.190 |
Why?
|
| Income | 1 | 2021 | 83 | 0.180 |
Why?
|
| Cell Line, Tumor | 10 | 2018 | 2552 | 0.180 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 207 | 0.180 |
Why?
|
| Observation | 1 | 2020 | 38 | 0.180 |
Why?
|
| Information Storage and Retrieval | 3 | 2005 | 121 | 0.180 |
Why?
|
| Uracil | 1 | 2000 | 55 | 0.180 |
Why?
|
| Benzenesulfonates | 2 | 2010 | 66 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2020 | 14 | 0.180 |
Why?
|
| Jews | 1 | 2020 | 42 | 0.180 |
Why?
|
| Aminopterin | 1 | 1999 | 5 | 0.180 |
Why?
|
| Oxidoreductases | 1 | 2000 | 112 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 833 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 91 | 0.170 |
Why?
|
| Bone Marrow | 2 | 2007 | 445 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 342 | 0.170 |
Why?
|
| Cetuximab | 4 | 2021 | 117 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.170 |
Why?
|
| Cytidine Deaminase | 1 | 2019 | 43 | 0.170 |
Why?
|
| Universities | 2 | 2010 | 146 | 0.160 |
Why?
|
| Pancreatectomy | 3 | 2016 | 158 | 0.160 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2019 | 83 | 0.160 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2020 | 58 | 0.160 |
Why?
|
| Melanoma | 2 | 2022 | 467 | 0.160 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 91 | 0.160 |
Why?
|
| Leukemia | 2 | 2006 | 323 | 0.160 |
Why?
|
| Multimodal Imaging | 1 | 2019 | 111 | 0.160 |
Why?
|
| Topotecan | 1 | 1998 | 45 | 0.160 |
Why?
|
| Nutrition Policy | 1 | 2018 | 13 | 0.160 |
Why?
|
| Adolescent | 5 | 2024 | 9237 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 133 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 273 | 0.160 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 540 | 0.160 |
Why?
|
| Capecitabine | 6 | 2016 | 98 | 0.160 |
Why?
|
| Palliative Care | 3 | 2018 | 263 | 0.160 |
Why?
|
| Nuts | 1 | 2018 | 3 | 0.160 |
Why?
|
| Seafood | 1 | 2018 | 10 | 0.150 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2018 | 34 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2022 | 575 | 0.150 |
Why?
|
| Organoids | 1 | 2018 | 62 | 0.150 |
Why?
|
| Multimedia | 1 | 1998 | 9 | 0.150 |
Why?
|
| Radiodermatitis | 1 | 1998 | 10 | 0.150 |
Why?
|
| Sarcopenia | 1 | 2018 | 13 | 0.150 |
Why?
|
| Reproducibility of Results | 5 | 2012 | 2752 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2019 | 90 | 0.150 |
Why?
|
| Hospital Information Systems | 2 | 1997 | 8 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2021 | 280 | 0.150 |
Why?
|
| Feasibility Studies | 4 | 2016 | 779 | 0.150 |
Why?
|
| Filgrastim | 1 | 2017 | 57 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2018 | 230 | 0.150 |
Why?
|
| Tumor Burden | 3 | 2016 | 308 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2011 | 161 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 51 | 0.150 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 463 | 0.150 |
Why?
|
| Receptors, Calcitriol | 1 | 2018 | 130 | 0.150 |
Why?
|
| Time Factors | 8 | 2021 | 5320 | 0.150 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 12 | 0.150 |
Why?
|
| Management Information Systems | 1 | 1997 | 3 | 0.140 |
Why?
|
| Surveys and Questionnaires | 6 | 2018 | 2612 | 0.140 |
Why?
|
| Computer Communication Networks | 1 | 1997 | 23 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 579 | 0.140 |
Why?
|
| Hematopoiesis | 2 | 1995 | 165 | 0.140 |
Why?
|
| Sex Factors | 2 | 2019 | 1063 | 0.140 |
Why?
|
| Age Factors | 2 | 2019 | 1867 | 0.140 |
Why?
|
| Skin Diseases | 1 | 1998 | 173 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 1998 | 167 | 0.140 |
Why?
|
| Postoperative Care | 1 | 2017 | 229 | 0.140 |
Why?
|
| Fishes | 1 | 2018 | 138 | 0.140 |
Why?
|
| Fractals | 1 | 2016 | 42 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 348 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 385 | 0.130 |
Why?
|
| Documentation | 1 | 1997 | 103 | 0.130 |
Why?
|
| Vomiting | 4 | 2016 | 194 | 0.130 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 1995 | 12 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 63 | 0.130 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 40 | 0.130 |
Why?
|
| Radiography, Thoracic | 2 | 2011 | 321 | 0.130 |
Why?
|
| Coffee | 1 | 2015 | 10 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 64 | 0.130 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 824 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 329 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2021 | 2863 | 0.130 |
Why?
|
| Mice | 9 | 2018 | 11737 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 51 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 433 | 0.120 |
Why?
|
| Cosmic Radiation | 1 | 1994 | 1 | 0.120 |
Why?
|
| Solar Activity | 1 | 1994 | 1 | 0.120 |
Why?
|
| Blood Cells | 1 | 1994 | 33 | 0.120 |
Why?
|
| Dasatinib | 2 | 2012 | 37 | 0.120 |
Why?
|
| Gamma Rays | 1 | 1994 | 73 | 0.120 |
Why?
|
| Protein Kinase C | 2 | 2008 | 268 | 0.120 |
Why?
|
| Animals | 18 | 2018 | 27317 | 0.120 |
Why?
|
| Immunotherapy | 4 | 2020 | 669 | 0.120 |
Why?
|
| Lymphatic Metastasis | 3 | 2015 | 502 | 0.120 |
Why?
|
| Acute Disease | 5 | 1999 | 841 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2013 | 2 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 309 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 38 | 0.110 |
Why?
|
| Health Status | 2 | 2015 | 370 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2015 | 684 | 0.110 |
Why?
|
| Insulin | 1 | 2019 | 1146 | 0.110 |
Why?
|
| Niacinamide | 2 | 2010 | 116 | 0.110 |
Why?
|
| Vesicular Transport Proteins | 1 | 2013 | 63 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 2 | 2005 | 217 | 0.110 |
Why?
|
| Computer Simulation | 1 | 1998 | 1097 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 103 | 0.110 |
Why?
|
| Phenylurea Compounds | 2 | 2010 | 114 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 576 | 0.110 |
Why?
|
| World Health Organization | 3 | 1999 | 106 | 0.110 |
Why?
|
| Phosphorylation | 5 | 2018 | 1130 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2009 | 390 | 0.110 |
Why?
|
| Cell Movement | 5 | 2018 | 783 | 0.110 |
Why?
|
| ErbB Receptors | 5 | 2011 | 500 | 0.110 |
Why?
|
| Folic Acid | 2 | 2003 | 63 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2012 | 2014 | 0.110 |
Why?
|
| Observer Variation | 4 | 2013 | 610 | 0.110 |
Why?
|
| Sirolimus | 2 | 2014 | 170 | 0.100 |
Why?
|
| Mitochondria | 1 | 2016 | 553 | 0.100 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2012 | 80 | 0.100 |
Why?
|
| Hyperthermia, Induced | 1 | 2013 | 73 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 182 | 0.100 |
Why?
|
| Thrombospondin 1 | 1 | 2011 | 21 | 0.100 |
Why?
|
| Tomography, Spiral Computed | 2 | 2018 | 77 | 0.100 |
Why?
|
| Symptom Assessment | 1 | 2012 | 66 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 2 | 2006 | 133 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2012 | 84 | 0.100 |
Why?
|
| Pyrroles | 2 | 2010 | 187 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2023 | 170 | 0.100 |
Why?
|
| Multidetector Computed Tomography | 1 | 2012 | 59 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 481 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 202 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2011 | 76 | 0.090 |
Why?
|
| Osteopontin | 1 | 2011 | 47 | 0.090 |
Why?
|
| Diarrhea | 4 | 2019 | 182 | 0.090 |
Why?
|
| Survivors | 1 | 2013 | 233 | 0.090 |
Why?
|
| Pulmonary Atelectasis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Interleukin-17 | 1 | 2011 | 105 | 0.090 |
Why?
|
| Administration, Oral | 7 | 2007 | 682 | 0.090 |
Why?
|
| Histones | 1 | 2012 | 329 | 0.090 |
Why?
|
| Reference Standards | 1 | 2010 | 144 | 0.090 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2011 | 85 | 0.090 |
Why?
|
| Proteasome Inhibitors | 2 | 2007 | 52 | 0.090 |
Why?
|
| Margins of Excision | 2 | 2022 | 39 | 0.090 |
Why?
|
| Biomarkers | 2 | 2014 | 1755 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2016 | 470 | 0.080 |
Why?
|
| Research Design | 1 | 2013 | 597 | 0.080 |
Why?
|
| Algorithms | 3 | 2012 | 1875 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2018 | 164 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2016 | 814 | 0.080 |
Why?
|
| Pain | 1 | 2011 | 400 | 0.080 |
Why?
|
| Protease Inhibitors | 2 | 2010 | 73 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2019 | 73 | 0.080 |
Why?
|
| Alanine | 2 | 2008 | 83 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2021 | 225 | 0.080 |
Why?
|
| Cancer Vaccines | 2 | 2007 | 160 | 0.080 |
Why?
|
| Models, Biological | 2 | 1997 | 1763 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
| DNA Repair | 2 | 2021 | 362 | 0.080 |
Why?
|
| Imatinib Mesylate | 2 | 2007 | 127 | 0.080 |
Why?
|
| Adenine | 1 | 2008 | 88 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2007 | 40 | 0.080 |
Why?
|
| Glycolipids | 1 | 2007 | 29 | 0.080 |
Why?
|
| Immunotoxins | 1 | 2007 | 14 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2009 | 213 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2023 | 1796 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 595 | 0.070 |
Why?
|
| Dermatology | 2 | 1998 | 40 | 0.070 |
Why?
|
| Morpholines | 2 | 2016 | 69 | 0.070 |
Why?
|
| Prevalence | 3 | 2020 | 1240 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 112 | 0.070 |
Why?
|
| Anus Neoplasms | 1 | 2007 | 36 | 0.070 |
Why?
|
| Software | 4 | 2012 | 665 | 0.070 |
Why?
|
| Azacitidine | 1 | 2008 | 146 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2016 | 1650 | 0.070 |
Why?
|
| Aortic Aneurysm | 1 | 2007 | 80 | 0.070 |
Why?
|
| Consensus | 2 | 2019 | 356 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2016 | 306 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 142 | 0.070 |
Why?
|
| Hepatectomy | 2 | 2007 | 170 | 0.070 |
Why?
|
| Wound Healing | 5 | 2014 | 359 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 193 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2007 | 234 | 0.070 |
Why?
|
| Thrombocytopenia | 5 | 2007 | 187 | 0.070 |
Why?
|
| Heterozygote | 2 | 2018 | 373 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 459 | 0.070 |
Why?
|
| Esophagogastric Junction | 2 | 2010 | 34 | 0.070 |
Why?
|
| Liver Diseases | 2 | 2007 | 242 | 0.070 |
Why?
|
| Paronychia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 364 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2022 | 178 | 0.070 |
Why?
|
| Doxycycline | 1 | 2006 | 28 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1855 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2023 | 313 | 0.070 |
Why?
|
| alpha-Galactosidase | 1 | 2005 | 5 | 0.070 |
Why?
|
| Fabry Disease | 1 | 2005 | 6 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2005 | 30 | 0.060 |
Why?
|
| Opportunistic Infections | 1 | 2006 | 60 | 0.060 |
Why?
|
| Carotid Artery, Common | 1 | 2005 | 28 | 0.060 |
Why?
|
| Drug Eruptions | 1 | 2005 | 34 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2018 | 327 | 0.060 |
Why?
|
| Subclavian Artery | 1 | 2005 | 43 | 0.060 |
Why?
|
| Receptor, trkA | 1 | 2005 | 15 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 86 | 0.060 |
Why?
|
| Prodrugs | 2 | 2004 | 49 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2018 | 2011 | 0.060 |
Why?
|
| Carbazoles | 1 | 2005 | 33 | 0.060 |
Why?
|
| Coronary Circulation | 1 | 2005 | 131 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2004 | 48 | 0.060 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 68 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2004 | 370 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 948 | 0.060 |
Why?
|
| Liposomes | 1 | 2004 | 93 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2005 | 98 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2007 | 319 | 0.060 |
Why?
|
| Vaccination | 2 | 2022 | 273 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2005 | 237 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 45 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 373 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 260 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2004 | 59 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 665 | 0.060 |
Why?
|
| Arginine | 1 | 2024 | 138 | 0.060 |
Why?
|
| Peritoneum | 1 | 2023 | 57 | 0.060 |
Why?
|
| Remission Induction | 1 | 2005 | 740 | 0.060 |
Why?
|
| Hematinics | 1 | 2003 | 11 | 0.060 |
Why?
|
| Bortezomib | 3 | 2010 | 82 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2004 | 287 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2008 | 657 | 0.050 |
Why?
|
| Flavonoids | 1 | 2003 | 87 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2006 | 331 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 136 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 783 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2002 | 24 | 0.050 |
Why?
|
| Antibody Formation | 2 | 2022 | 171 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2019 | 112 | 0.050 |
Why?
|
| Granulation Tissue | 3 | 1969 | 15 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| DNA, Antisense | 1 | 2002 | 15 | 0.050 |
Why?
|
| Apoptosis | 3 | 2016 | 1716 | 0.050 |
Why?
|
| Marital Status | 1 | 2022 | 42 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 336 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 55 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2006 | 786 | 0.050 |
Why?
|
| Piperidines | 1 | 2003 | 164 | 0.050 |
Why?
|
| Fatigue | 2 | 2019 | 179 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2005 | 567 | 0.050 |
Why?
|
| Ascites | 1 | 2022 | 56 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 60 | 0.050 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2001 | 36 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 148 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 155 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2021 | 56 | 0.050 |
Why?
|
| Angiopoietin-2 | 1 | 2021 | 17 | 0.050 |
Why?
|
| ras Proteins | 2 | 2013 | 130 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2002 | 274 | 0.050 |
Why?
|
| Microtubules | 2 | 2016 | 123 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2001 | 84 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 176 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 93 | 0.050 |
Why?
|
| France | 1 | 2021 | 48 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 21 | 0.050 |
Why?
|
| Platinum Compounds | 1 | 2020 | 31 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2004 | 469 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2005 | 685 | 0.050 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2000 | 29 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 426 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 309 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1223 | 0.040 |
Why?
|
| Israel | 1 | 2020 | 57 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 1837 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2024 | 607 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2005 | 975 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 101 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 208 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 57 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2014 | 509 | 0.040 |
Why?
|
| Constipation | 1 | 2020 | 63 | 0.040 |
Why?
|
| Acetals | 1 | 1999 | 3 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2019 | 57 | 0.040 |
Why?
|
| Thoracic Neoplasms | 1 | 2019 | 64 | 0.040 |
Why?
|
| International Cooperation | 1 | 1999 | 125 | 0.040 |
Why?
|
| Contrast Media | 1 | 2004 | 1090 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 63 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 298 | 0.040 |
Why?
|
| Child | 1 | 2010 | 7149 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 519 | 0.040 |
Why?
|
| Protein Methyltransferases | 1 | 2018 | 15 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 1998 | 25 | 0.040 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 1999 | 35 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1998 | 34 | 0.040 |
Why?
|
| Area Under Curve | 3 | 2004 | 337 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 49 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 299 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 988 | 0.040 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Nutritive Value | 1 | 2018 | 6 | 0.040 |
Why?
|
| Diet Records | 1 | 2018 | 19 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2020 | 599 | 0.040 |
Why?
|
| Power Plants | 1 | 1998 | 5 | 0.040 |
Why?
|
| Energy Intake | 1 | 2018 | 97 | 0.040 |
Why?
|
| Ukraine | 1 | 1998 | 19 | 0.040 |
Why?
|
| Sulfones | 1 | 2018 | 45 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 727 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 443 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 1 | 2018 | 99 | 0.040 |
Why?
|
| Quinolones | 1 | 2018 | 60 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 1998 | 83 | 0.040 |
Why?
|
| Antiemetics | 1 | 1999 | 98 | 0.040 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 161 | 0.040 |
Why?
|
| Illinois | 1 | 2019 | 472 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 565 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 424 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 192 | 0.040 |
Why?
|
| Cost Control | 1 | 1997 | 45 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 216 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 557 | 0.040 |
Why?
|
| Epithelioid Cells | 1 | 2016 | 13 | 0.040 |
Why?
|
| Global Health | 1 | 1998 | 186 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2018 | 426 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 1997 | 59 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 657 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2007 | 105 | 0.030 |
Why?
|
| Veratrum Alkaloids | 1 | 2016 | 10 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2016 | 40 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 66 | 0.030 |
Why?
|
| CA-19-9 Antigen | 1 | 2016 | 12 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 269 | 0.030 |
Why?
|
| Anemia | 3 | 2007 | 129 | 0.030 |
Why?
|
| Radiography | 2 | 2010 | 809 | 0.030 |
Why?
|
| Lymphokines | 2 | 2002 | 76 | 0.030 |
Why?
|
| Leukopenia | 2 | 2007 | 66 | 0.030 |
Why?
|
| Tea | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.030 |
Why?
|
| Autoradiography | 3 | 1967 | 69 | 0.030 |
Why?
|
| Total Lung Capacity | 1 | 2015 | 5 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 273 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 135 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 181 | 0.030 |
Why?
|
| Hemodynamics | 2 | 2018 | 729 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 127 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2004 | 3443 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1140 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 369 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 1995 | 40 | 0.030 |
Why?
|
| Systems Integration | 1 | 1995 | 36 | 0.030 |
Why?
|
| Space Flight | 1 | 1994 | 7 | 0.030 |
Why?
|
| Decision Trees | 1 | 1995 | 59 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 2014 | 16 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 162 | 0.030 |
Why?
|
| Aerospace Medicine | 1 | 1994 | 17 | 0.030 |
Why?
|
| Anthropometry | 1 | 1995 | 75 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 771 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1995 | 223 | 0.030 |
Why?
|
| Caffeine | 1 | 2015 | 83 | 0.030 |
Why?
|
| cdc25 Phosphatases | 1 | 2014 | 19 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 353 | 0.030 |
Why?
|
| Mathematics | 1 | 1994 | 191 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1994 | 188 | 0.030 |
Why?
|
| Colon | 1 | 2018 | 509 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 124 | 0.030 |
Why?
|
| SEER Program | 1 | 2014 | 197 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 1574 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 194 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 91 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2014 | 101 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1994 | 173 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 1994 | 225 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 1995 | 160 | 0.030 |
Why?
|
| Education, Medical | 1 | 1997 | 243 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.030 |
Why?
|
| Stomatitis | 2 | 2004 | 30 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 267 | 0.030 |
Why?
|
| Dogs | 1 | 1994 | 704 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1592 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 778 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2024 | 2275 | 0.030 |
Why?
|
| Lung Volume Measurements | 1 | 2013 | 20 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 292 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 1096 | 0.030 |
Why?
|
| Rats | 4 | 1994 | 4040 | 0.030 |
Why?
|
| Patient Selection | 2 | 2013 | 682 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 390 | 0.030 |
Why?
|
| Breast | 1 | 1995 | 292 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 114 | 0.030 |
Why?
|
| Acetylation | 1 | 2012 | 132 | 0.030 |
Why?
|
| Family | 1 | 2014 | 325 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2012 | 18 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 136 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2014 | 463 | 0.030 |
Why?
|
| Bone Neoplasms | 2 | 2010 | 329 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2012 | 273 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 299 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 104 | 0.030 |
Why?
|
| Proteins | 3 | 1963 | 786 | 0.020 |
Why?
|
| alpha 1-Antichymotrypsin | 1 | 2011 | 4 | 0.020 |
Why?
|
| Liver | 3 | 2004 | 1205 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 19 | 0.020 |
Why?
|
| Ploidies | 1 | 2011 | 41 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 85 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 86 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 423 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 71 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 338 | 0.020 |
Why?
|
| Psychometrics | 1 | 2012 | 329 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2011 | 208 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 354 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 415 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 477 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 123 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1997 | 889 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 245 | 0.020 |
Why?
|
| Muscle, Skeletal | 3 | 2004 | 466 | 0.020 |
Why?
|
| Taxoids | 1 | 2009 | 130 | 0.020 |
Why?
|
| Mucositis | 1 | 2009 | 18 | 0.020 |
Why?
|
| Haptens | 2 | 1988 | 9 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 2008 | 22 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2008 | 14 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1182 | 0.020 |
Why?
|
| Obesity | 1 | 1995 | 966 | 0.020 |
Why?
|
| Fibronectins | 1 | 1988 | 101 | 0.020 |
Why?
|
| Mitomycin | 1 | 2007 | 29 | 0.020 |
Why?
|
| Lipid Droplets | 1 | 2007 | 16 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 44 | 0.020 |
Why?
|
| Tritium | 2 | 1967 | 133 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 2495 | 0.020 |
Why?
|
| Leucine | 2 | 1967 | 60 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 261 | 0.020 |
Why?
|
| Genes, Intracisternal A-Particle | 1 | 2007 | 3 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 20 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 92 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 240 | 0.020 |
Why?
|
| Pelvis | 1 | 2007 | 96 | 0.020 |
Why?
|
| Cortisone | 1 | 1967 | 9 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 113 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2007 | 80 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 1998 | 155 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1969 | 302 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2007 | 69 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2010 | 465 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 470 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1969 | 357 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 590 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 401 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 71 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 77 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 85 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 921 | 0.020 |
Why?
|
| Hyperemia | 1 | 2005 | 19 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 117 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3209 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2007 | 691 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 125 | 0.020 |
Why?
|
| Microcirculation | 1 | 2005 | 104 | 0.020 |
Why?
|
| Furans | 1 | 2005 | 16 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2007 | 493 | 0.020 |
Why?
|
| Avidin | 1 | 1984 | 5 | 0.020 |
Why?
|
| Phenylenediamines | 1 | 2004 | 7 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 120 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 245 | 0.020 |
Why?
|
| Biotin | 1 | 1984 | 45 | 0.020 |
Why?
|
| Cell Survival | 1 | 2007 | 982 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2004 | 12 | 0.020 |
Why?
|
| Ovalbumin | 1 | 1984 | 109 | 0.010 |
Why?
|
| Transaminases | 1 | 2004 | 33 | 0.010 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2004 | 33 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2006 | 698 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 92 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 340 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 153 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 161 | 0.010 |
Why?
|
| Connective Tissue Cells | 1 | 1963 | 1 | 0.010 |
Why?
|
| Connective Tissue | 1 | 1963 | 23 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2004 | 397 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 207 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1964 | 183 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1591 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2004 | 264 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2004 | 371 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2004 | 202 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2004 | 225 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2008 | 1265 | 0.010 |
Why?
|
| Research | 1 | 1963 | 252 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2006 | 570 | 0.010 |
Why?
|
| Protein Kinase C-alpha | 1 | 2002 | 27 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 56 | 0.010 |
Why?
|
| Thionucleotides | 1 | 2002 | 56 | 0.010 |
Why?
|
| Razoxane | 1 | 2001 | 3 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 2327 | 0.010 |
Why?
|
| Oxonic Acid | 1 | 2001 | 8 | 0.010 |
Why?
|
| Tegafur | 1 | 2001 | 17 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2004 | 463 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2002 | 92 | 0.010 |
Why?
|
| Interferons | 1 | 2002 | 124 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 202 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3027 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 168 | 0.010 |
Why?
|
| Carcinoma | 1 | 2004 | 443 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2001 | 298 | 0.010 |
Why?
|
| Phenotype | 1 | 2007 | 2439 | 0.010 |
Why?
|
| Muscles | 2 | 1952 | 193 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2002 | 215 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1963 | 755 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2002 | 171 | 0.010 |
Why?
|
| Electrophoresis, Paper | 1 | 1959 | 2 | 0.010 |
Why?
|
| Knee | 1 | 1959 | 17 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 332 | 0.010 |
Why?
|
| Perfusion | 3 | 1969 | 235 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 650 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1959 | 145 | 0.010 |
Why?
|
| Granisetron | 1 | 1999 | 8 | 0.010 |
Why?
|
| Appendicitis | 1 | 1959 | 64 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 1999 | 35 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2001 | 461 | 0.010 |
Why?
|
| Knee Joint | 1 | 1959 | 165 | 0.010 |
Why?
|
| Antibiotics, Antitubercular | 1 | 1958 | 4 | 0.010 |
Why?
|
| Osteomyelitis | 1 | 1958 | 55 | 0.010 |
Why?
|
| Cytokines | 1 | 2002 | 802 | 0.010 |
Why?
|
| Dermatologic Agents | 1 | 1958 | 73 | 0.010 |
Why?
|
| Triazines | 1 | 1997 | 53 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1999 | 344 | 0.010 |
Why?
|
| Growth Substances | 1 | 1997 | 80 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1997 | 94 | 0.010 |
Why?
|
| Radiometry | 1 | 1997 | 56 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1997 | 172 | 0.010 |
Why?
|
| Empyema | 1 | 1956 | 9 | 0.010 |
Why?
|
| Empyema, Pleural | 1 | 1956 | 10 | 0.010 |
Why?
|
| Pheochromocytoma | 1 | 1956 | 49 | 0.010 |
Why?
|
| Syndrome | 1 | 1997 | 449 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1999 | 461 | 0.010 |
Why?
|
| Giant Cell Tumors | 1 | 1955 | 3 | 0.010 |
Why?
|
| Bone Cysts | 1 | 1955 | 8 | 0.010 |
Why?
|
| Cysts | 1 | 1955 | 106 | 0.010 |
Why?
|
| Switzerland | 1 | 1973 | 17 | 0.010 |
Why?
|
| Education, Nursing, Continuing | 1 | 1973 | 9 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 1768 | 0.010 |
Why?
|
| Liver Circulation | 2 | 1969 | 29 | 0.010 |
Why?
|
| Foot Deformities | 1 | 1952 | 6 | 0.010 |
Why?
|
| Flatfoot | 1 | 1952 | 7 | 0.010 |
Why?
|
| Teaching | 1 | 1973 | 147 | 0.010 |
Why?
|
| Hepatic Encephalopathy | 2 | 1969 | 39 | 0.010 |
Why?
|
| Foot | 1 | 1952 | 52 | 0.010 |
Why?
|
| Leg | 1 | 1952 | 140 | 0.010 |
Why?
|
| Knee Dislocation | 1 | 1951 | 5 | 0.010 |
Why?
|
| Patellar Dislocation | 1 | 1951 | 12 | 0.010 |
Why?
|
| Relaxation | 1 | 1950 | 2 | 0.010 |
Why?
|
| Knee Injuries | 1 | 1951 | 54 | 0.010 |
Why?
|
| Learning | 1 | 1973 | 285 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1969 | 27 | 0.010 |
Why?
|
| Assisted Circulation | 1 | 1969 | 16 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1988 | 51 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1988 | 71 | 0.010 |
Why?
|
| Gelatin | 1 | 1988 | 25 | 0.010 |
Why?
|
| Clone Cells | 1 | 1988 | 214 | 0.000 |
Why?
|
| Heparin | 1 | 1988 | 185 | 0.000 |
Why?
|
| Aminocaproates | 1 | 1984 | 4 | 0.000 |
Why?
|
| Dinitrobenzenes | 1 | 1984 | 5 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1984 | 146 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1984 | 177 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1984 | 308 | 0.000 |
Why?
|
| Lysine | 1 | 1984 | 150 | 0.000 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1984 | 374 | 0.000 |
Why?
|
| Swine | 3 | 1969 | 581 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1988 | 2880 | 0.000 |
Why?
|
| Peptides | 1 | 1984 | 646 | 0.000 |
Why?
|
| Bile | 2 | 1969 | 57 | 0.000 |
Why?
|
| Sulfobromophthalein | 1 | 1969 | 1 | 0.000 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1969 | 18 | 0.000 |
Why?
|
| Methods | 1 | 1969 | 151 | 0.000 |
Why?
|
| Hematocrit | 1 | 1969 | 68 | 0.000 |
Why?
|
| Extracorporeal Circulation | 1 | 1969 | 34 | 0.000 |
Why?
|
| Electrolytes | 1 | 1969 | 52 | 0.000 |
Why?
|
| Bicarbonates | 1 | 1969 | 58 | 0.000 |
Why?
|
| Alanine Transaminase | 1 | 1969 | 71 | 0.000 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1969 | 71 | 0.000 |
Why?
|
| Aspartate Aminotransferases | 1 | 1969 | 74 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1969 | 132 | 0.000 |
Why?
|
| Bilirubin | 1 | 1969 | 129 | 0.000 |
Why?
|
| Hemoglobins | 1 | 1969 | 192 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1969 | 499 | 0.000 |
Why?
|
| Oxygen | 1 | 1969 | 742 | 0.000 |
Why?
|